Scotiabank raised the firm’s price target on Travere Therapeutics (TVTX) to $27 from $23 and keeps an Outperform rating on the shares. The company posted a “solid” Q3 print, which highlighted the strength of Filspari’s ongoing launch in IgA nephropathy, or Berger’s Disease, the analyst tells investors.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $20 from $18 at Barclays
- Travere Therapeutics Boosts Sales with FILSPARI Approval
- Travere Therapeutics reports Q3 adjusted EPS (46c), consensus (68c)
- Travere presents data reinforcing clinical benefit of FILSPARI in IgAN
- Wells Fargo upgrades Travere Therapeutics to Overweight on further upside